Past Collaborations
My Services
Innovative consulting solutions to achieve impactful results
As a seasoned consultant for the pharmaceutical industry and an active member of multiple advisory boards, Dr. Isaacs provides strategic insights for cutting-edge diabetes solutions and ensures the highest standards in diabetes care.
As a seasoned consultant for the pharmaceutical industry and an active member of multiple advisory boards, Dr. Isaacs provides strategic insights for cutting-edge diabetes solutions and ensures the highest standards in diabetes care.
An authority in diabetes content
With over 80 peer reviewed publications, Dr. Isaacs stands as a leading authority in diabetes content.
Offering expert writing services, she has repeatedly transformed diabetes research and clinical practice insights into engaging manuscripts, reports, and educational materials.
Elevating diabetes care through compelling speaking engagements
Dr. Isaacs is renowned for her captivating speaking engagements that educate and inspire clinicians and patient advocates.
She has been a speaker for leading organizations including the American Diabetes Association, the Association of Diabetes Care and Education Specialists, the American Association of Clinical Endocrinology, and the American Heart Association.
In addition, she frequently delivers continuing medical education (CME) programs to equip providers with the latest knowledge and skills.
What I've Been Working on
Consulting
Speaking
Medical Writing
CME
My Expertise
Recent Presentations
Recent Publications
Recent Podcasts
Videos
X Timeline
In this #DiabetesDialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Roy Beck, MD, PhD, to discuss the INHALE-3 trial, evaluating technosphere inhaled insulin (Afrezza) v. standard diabetes therapies.
🔗 https://www.hcplive.com/view/diabetes-dialogue-inhale-3-trial-and-afrezza-with-roy-beck-md-phd
#Endocrinology #Podcast
Orforglipron is being tested in a dedicated trial for #Hypertension Will the results change how we approach BP management?
Thrilled to announce the release of the new @ADA_DiabetesPro Consensus Statement: #MASLD is now recognized as a major metabolic complication in type 2 diabetes and obesity, underscoring the central role of insulin resistance and cardiometabolic risk factors in its pathogenesis.…